Replimune Group, Inc. (NASDAQ:REPL) Stock Has Consensus Price Target of $14.33 According to Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $14.33.

REPL has been the subject of a number of research reports. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a report on Friday, August 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Replimune Group in a research report on Wednesday, November 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. Leerink Partners boosted their target price on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Finally, Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st.

Insider Activity

In other news, Director Kapil Dhingra sold 21,500 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $19.00, for a total value of $408,500.00. Following the sale, the director owned 21,669 shares of the company’s stock, valued at $411,711. The trade was a 49.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Joseph P. Slattery sold 5,200 shares of the stock in a transaction on Monday, November 9th. The stock was sold at an average price of $21.80, for a total transaction of $113,360.00. Following the transaction, the director owned 1,467 shares of the company’s stock, valued at $31,980.60. The trade was a 78.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 35,956 shares of company stock worth $654,036 over the last ninety days. Insiders own 5.40% of the company’s stock.

Institutional Trading of Replimune Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantinno Capital Management LP grew its holdings in Replimune Group by 782.7% during the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock worth $830,000 after purchasing an additional 96,188 shares during the period. Montanova Capital LLC increased its position in Replimune Group by 4.0% during the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after buying an additional 168,000 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in Replimune Group in the first quarter valued at approximately $921,000. Squarepoint Ops LLC bought a new stake in Replimune Group in the second quarter valued at approximately $1,454,000. Finally, Deutsche Bank AG bought a new stake in Replimune Group in the second quarter valued at approximately $857,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Down 6.4%

Shares of NASDAQ REPL opened at $21.78 on Friday. The company has a fifty day moving average price of $14.51 and a 200 day moving average price of $9.89. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. Replimune Group has a 1-year low of $1.50 and a 1-year high of $23.54.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.24. As a group, equities analysts expect that Replimune Group will post -2.40 EPS for the current year.

Replimune Group Company Profile

Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.